Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $143.4 million.

  • Cartesian Therapeutics' Cash & Current Investments fell 3458.7% to $143.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $143.4 million, marking a year-over-year decrease of 3458.7%. This contributed to the annual value of $212.6 million for FY2024, which is 17643.64% up from last year.
  • According to the latest figures from Q3 2025, Cartesian Therapeutics' Cash & Current Investments is $143.4 million, which was down 3458.7% from $160.3 million recorded in Q2 2025.
  • Cartesian Therapeutics' Cash & Current Investments' 5-year high stood at $219.2 million during Q3 2024, with a 5-year trough of $76.9 million in Q4 2023.
  • Over the past 5 years, Cartesian Therapeutics' median Cash & Current Investments value was $138.7 million (recorded in 2021), while the average stood at $137.2 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' Cash & Current Investments crashed by 4564.2% in 2023, and later surged by 17643.64% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' Cash & Current Investments (Quarter) stood at $128.1 million in 2021, then grew by 5.11% to $134.6 million in 2022, then tumbled by 42.86% to $76.9 million in 2023, then surged by 176.44% to $212.6 million in 2024, then plummeted by 32.56% to $143.4 million in 2025.
  • Its Cash & Current Investments was $143.4 million in Q3 2025, compared to $160.3 million in Q2 2025 and $180.4 million in Q1 2025.